S2G Investments led a $25m Series A funding round in Faeth Therapeutics.

S2G Investments, a multi-stage investment firm, led a $25m Series A funding round in Faeth Therapeutics, a clinical-stage biotechnology company, with participation from Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, Cantos, B Group Capital, Avicella, and THO Seed Fund. “I believe recent phase 3 studies are showing validation of multi-node targeting. In my view, insider participation in this financing reflects conviction in Faeth’s progress, while new investors recognize metabolism as a category entering the clinic. Based on emerging evidence, Faeth’s selective multi-node approach appears well suited to capture value as metabolism gains recognition as a potential new pillar of cancer treatment," Sanjeev Krishnan, S2G Investments Managing Partner.